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Introduction 14 
The discovery of norovirus in 19721, changed the understanding of the aetiology of gastroenteritis, 15 
making it the virus to be identified as an agent of gastroenteritis in humans. 16 
Today, norovirus is recognised as one of the commonest human infections and estimated to be 17 
associated with 125 million cases and 35,000 deaths worldwide in 20102. Better epidemiological 18 
surveillance and outbreak investigations3, coupled with wider implementation of molecular-based 19 
laboratory diagnostics4 are leading to better estimates of the burden of norovirus infections as well as 20 
improved outbreak control. 21 
Data from challenge studies of prototype norovirus vaccines5, 6 demonstrated that protection against 22 
infection and disease can be achieved, however there remain significant challenges to development of 23 
a norovirus vaccine. Recent advances in cell culture systems for norovirus7, 8 and current research 24 
investigating the distribution of norovirus-associated disease in the population, for whom the disease 25 
burden is greatest, understanding host susceptibility factors, how to deploy novel technologies detecting 26 
norovirus in food and environmental matrices, and methodologies for ascertaining cases, are important 27 
in increasing our understanding of norovirus. Answers to these will help design strategies for vaccine 28 
and antiviral development, and how these might be best deployed to control norovirus infection. 29 
 30 
Norovirus virology 31 
At the time of discovery, the virus was referred to as the Norwalk agent, but as other related viruses 32 
were described in association with gastroenteritis, they became known as Norwalk-like viruses (NLVs), 33 
or – based on their morphology by electron microscopy – small, round, structured viruses (SLSVs). 34 
Following the cloning and sequencing of the Norwalk agent genome in 19939, and subsequently other 35 
NLVs10, defining the genetic relatedness of these viruses led to their reclassification in the Caliciviridae 36 
family of viruses under the genus Norovirus in 200211. 37 
Classification of this genetically diverse group of viruses12, 13 has described six established14 38 
genogroups (GI-GVI), and a proposed seventh15, 16. Two genogroups (GI and GII) are important 39 
pathogens of humans (GII also contains pathogens of animals, but there is no evidence of zoonotic 40 
transmission17) and genogroups are further subdivided into genotypes: nine GI and twenty-two GII 41 
genotypes have been described12-14. Norovirus names are presented as genotypes, e.g. genogroup II-42 
genotype 4 (GII.4) and strains are named for the place and year of their first description: e.g. GII.4/New 43 
Orleans 200918 or GII.4/Sydney 201219. 44 
The norovirus genome is a single strand of positive-sense ribonucleic acid (+ssRNA) that is ~7700 45 
nucleotides in length, organised as three open reading frames (ORF1-3)20. The 5′-proximal ORF1 46 
encodes a polyprotein that is post-translationally processed by the virus-encoded protease into six non-47 
structural proteins, including a genome-linked protein (VPg/NS5), protease (Pro/NS6) and an RNA-48 
dependent RNA polymerase (RdRp/NS7). Both ORF2 and ORF3 encode a single protein each, VP1 49 
and VP2 respectively, that are structural proteins involved in formation and stabilisation of the virus 50 
particle21. 51 
Norovirus particles are 27-35nm in diameter and comprised of 180 copies of the VP1 protein, which 52 
itself is organised into three main domains: N-terminal (N), shell (S) and protruding (P), which is further 53 
arranged as P1 (subdivided as P1.1 and P1.2) and P221. In the mature infectious virus particle, the N 54 
domain is internal, and the P2 domain is the most external part of the virus, making it highly surface-55 
exposed and placed to coordinate many of the interactions between norovirus and its host environment. 56 
The primary host cell receptor for human norovirus is unknown, but can interact with histo-blood group 57 
antigens (HBGAs)22; these are glycans expressed on epithelial cells and in mucosal secretions, which 58 
determine ABO blood type groups. Norovirus strains may use HBGAs as attachment factors or co-59 
receptors23, and sites in the VP1 P2 domain have been identified as HBGA binding sites24-29. Synthesis 60 
of HBGAs occurs by sequential modification of a precursor, and the process is controlled by glycosyl-61 
transferase enzymes from several genetic loci that exhibit polymorphism throughout the human 62 
population. The ABH and Lewis antigens are relevant to norovirus binding, and as such the phenotype 63 
of an individual for secretory ABH and Lewis antigens is a host susceptibility factor for norovirus 64 
infection. Specifically, individuals with a non-functional FUT2 gene, which encodes an α1,2-65 
fucosyltrasnferase, have a ‘non-secretor’ phenotype, and are more resistant to norovirus infection that 66 
‘secretor’ individuals30, 31. Polymorphism at this locus may modulate susceptibility to other causes of 67 
diarrhoeal disease32.  68 
Public health laboratory surveillance worldwide has demonstrated dominance of GII.4 viruses33-36, 69 
however other norovirus genotypes circulate consistently, if at a lower level, in the population. The GII.4 70 
cluster of norovirus strains have been the most commonly detected noroviruses circulating worldwide 71 
since the mid-1990s, over time, distinct variants of the GII.4 virus evolve, emerge, and then recede to 72 
be replaced by a new variant33. Emergence of a new GII.4 variant is associated with higher levels of 73 
infection and illness in the population and increased numbers of outbreaks37, although severity of 74 
disease does not necessarily increase. These emergence events may be geographically contained (e.g. 75 
a 2003 variant emerged in Asia, and a 2006 variant spread in Europe)38, or may be global, with new 76 
variants emerging and spreading worldwide over the course of a single year (as seen in 200239, 200640, 77 
200918 and 201219). 78 
Noroviruses have been shown to have high evolutionary rates, up to 10-2 substitutions/site/year in the 79 
VP1 protein41, due to the error-prone nature of the virus-encoded RdRp42. The rate of evolution is fastest 80 
in the P2 domain, which interacts with the host immune system. Immune response to norovirus infection 81 
appears to target this region of the virus capsid, and epitopes in this domain have been identified as 82 
important in defining the antigenic profile of GII.4 norovirus strains43-47, leading to the emergence of 83 
antigenically distinct viruses in the population, associated with epidemic/pandemic waves of 84 
gastroenteritis33, 37, 48, 49. 85 
The emergence of variant GII.4 strains is associated with mutations occurring in the virus at epitope A 86 
(VP1 amino acid positions 296-298, 368 & 372) and D (VP1 amino acid positions 393-395)44, 50. 87 
Mutations, particularly in epitopes A and D, will be selected for in the virus population if the mutations 88 
are such that existing immunity in the host population is evaded by the mutated virus, but the virus is 89 
otherwise not disadvantaged. Because much of the human population is exposed to antigenically similar 90 
noroviruses at a similar time, virus-specific immunity is likely similar between many people. As a result, 91 
the variant norovirus is advantaged, being more likely to successfully evade existing immunity, and 92 
subsequently establish more infections and be transmitted. In this way, the virus can spread quickly 93 
through the population. Eventually infections generate new immunological responses, which ultimately 94 
limit the success of this variant in the population, but in turn creates an ecological niche favourable for 95 
a new variant, and the process cycles again. This process has been observed for GII.4 noroviruses 96 
throughout the 1990s, 2000s and 2010s19, 33, 37, 45, 47. 97 
 98 
Norovirus surveillance 99 
Surveillance of norovirus is complicated because most people do not contact medical services when 100 
they are ill. In the UK, it is suggested that for each laboratory report of norovirus around 300 cases go 101 
unreported51. This is largely related to the nature of the illness itself. The virus is highly infectious with 102 
an estimated infectious dose of around 10-100 virus particles (virions) needed to cause infection52, with 103 
a high probability of infection from ingesting a single particle53. It has a short incubation period, 104 
anywhere between 12 and 72 hours, and symptoms typically last for around 24- 48 hours54. Despite 105 
these difficulties it is still recognised as the commonest cause of gastrointestinal disease, not just in the 106 
UK, but worldwide55. In the UK it is estimated between 3 and 4 million cases occur annually51, 56, at a 107 
cost of £106 million to patients and the health care services. In the USA this estimate is around 21 108 
million domestically acquired cases57. Infections with norovirus occur in all age groups, however, the 109 
highest incidence is in children aged less than five years56, 58. 110 
 111 
The illness is often described as generally mild and self-limiting. The description of a mild infection can 112 
trivialise the effect of the illness; in England it has been estimated that 3000 admissions occur annually 113 
as a result of norovirus infection in adults59 or 0.3% of emergency admissions in those aged over 65, 114 
and 0.1% in adults aged 16-64 years. The consequences of infection are also greater in vulnerable 115 
populations. In a study in the county of Avon, UK, hospital patients were ill for longer than care home 116 
residents and staff working in the hospitals or care home, with around 10% of inpatients affected still 117 
showing symptoms 7 days after becoming ill60. There is also evidence that norovirus can contribute to 118 
mortality in the elderly. Modelling of deaths suggests that norovirus is associated with 20% in those 119 
aged over 65 years who died of infectious intestinal disease, and that 13% of deaths caused by non-120 
infectious intestinal disease61. 121 
Public Health England have conducted surveillance of gastrointestinal disease outbreaks since 199262. 122 
Analysis of the first nine years of data highlighted the importance of norovirus outbreaks in hospitals; 123 
over 80% of all reported outbreaks in hospitals were suspected or confirmed as norovirus, and 25% of 124 
all general outbreaks occurred in hospitals63. 125 
 126 
Recent developments 127 
 128 
Surveillance 129 
Since the recognition of the importance of norovirus as a cause of GI disease a more detailed online 130 
surveillance system was set up in 200963. The online system increased ascertainment of outbreaks in 131 
hospitals, with more outbreaks reported in the first year than the whole of the preceding system63. Both 132 
systems highlighted the increased activity during the winter months, and the considerable burden it 133 
places on NHS hospitals in England. The online system suggests around 13000 patients and 3000 staff 134 
are affected each year, moreover, almost 9000 bed days are lost because of restrictions to admissions 135 
during outbreaks63. 136 
The key to surveillance of norovirus is allying the epidemiology with surveillance of virology. It is often 137 
difficult to achieve this. Recording the number of outbreaks, and laboratory reports indicates levels of 138 
infection, but they cannot directly ally this knowledge of circulating strains of the virus. The activity 139 
recorded in both Public Health England’s hospital outbreak reporting scheme and laboratory reports 140 
suggests that seasonal activity varies considerably. The reasons for changes in seasonal activity need 141 
unpicking and modelling of changes in the circulating strains of norovirus against laboratory reporting 142 
provided evidence that modifications within the virus itself leads to changes in the epidemiology. In the 143 
autumn/winter of 2012 PHE recorded increased levels of norovirus activity; later attributed to the 144 
emergence of the Sydney 2012 strain37. However, other reasons have been proposed, such as changes 145 
in winter conditions such as falling temperature64. 146 
Given the difficulty in surveillance of norovirus infections from direct sources, other developments need 147 
to be explored. For example, social media could provide early indications of increasing activity. There 148 
are a number of publications looking at the use of internet search and social media postings to provide 149 
information on increased disease activity65-67. Other forms of syndromic surveillance have been used 150 
such as the use of telephone helpline data to map diarrhoea and vomiting68, difficulties with this 151 
approach fall mainly on disentangling the causes of the illness from syndromes (diarrhoea and 152 
vomiting). Norovirus is not the only cause of D&V and has a seasonality similar to that of rotavirus, 153 
similarly sapovirus has similar illness characteristics to norovirus. 154 
 155 
Virus culture systems 156 
Understanding the interactions of norovirus with host cells has been limited by the lack of an in vitro 157 
laboratory cell culture system. Attempts to establish conventional cell culture approaches were 158 
unsuccessful69, after which alternative approaches were developed70, 71, however, these were limited in 159 
their usefulness. 160 
More recently, progress has been made towards development of laboratory culture systems for human 161 
norovirus. Two systems have been described: one describes human norovirus replication in B cells8, 162 
and a second which describes human norovirus replication supported by stem cell-derived human 163 
enteroids7. These systems present exciting new opportunities to understand how norovirus interacts 164 
both with the host cell and with the host environment. 165 
The system using human enteroids7 provides a model for processes of norovirus replication such as 166 
attachment/entry, genome replication, and virus assembly/release can be interrogated in a biologically 167 
relevant cell type. Advances in these areas will be crucial for identifying targets for virus-specific 168 
interventions, and evaluating how effective different antiviral therapies can limit norovirus replication. 169 
Further insights into virus entry and egress will enhance understanding of the interactions between virus 170 
and host receptors and identify novel interactions between virus and host that serve as intervention 171 
targets, for example antibodies which interfere with attachment or release processes, thus neutralising 172 
free virus. 173 
The second system, in which norovirus replication is supported in B cells, uses commensal bacteria 174 
that express HBGAs to facilitate virus replication in this model8, 72. Analysis of norovirus replication in 175 
this system could enhance understanding of the interaction between norovirus and HBGAs – and 176 
identify how these interactions might be disrupted– but also what interactions might occur with, and 177 
what role might be played by, the microbiome during norovirus infection73. 178 
 179 
Norovirus vaccines 180 
Modelling studies have shown that norovirus vaccination would offer healthcare and economic benefit74. 181 
These could help control and prevent the large-scale and often protracted outbreaks often seen in 182 
healthcare settings75 and other settings such as in the military76, 77. 183 
Until very recently, development of candidate vaccines focussed on recombinant protein systems; 184 
expression of the norovirus capsid protein VP1 in vitro leads to self-assembly of the protein into virus-185 
like particles (VLPs) that are antigenically and morphologically identical to infectious virus, but lacking 186 
a genome, VLPs are entirely non-infectious78. 187 
Early clinical studies of responses in humans to immunisation with VLPs demonstrated they were 188 
immunogenic when delivered orally79, 80 or intranasally81. A randomised, double-blind placebo-189 
controlled trial conducted in healthy, susceptible adult volunteers investigated the safety and efficacy 190 
of vaccination using norovirus VLPs, followed by challenge with a homologous norovirus strain6. This 191 
trial demonstrated 70% of vaccine recipients had a virus-specific IgA response, and vaccination reduced 192 
the frequency of both infection and disease between placebo control group and vaccine recipients6. 193 
However, the prototype vaccine (and challenge strain) used in this trial was based on a single norovirus 194 
strain – the prototype GI.1 Norwalk virus/1968 – which is uncommon, detected in <1% of norovirus 195 
strains characterised per year in surveillance programmes in developed countries. As the most 196 
significant disease burden is associated with the GII.4 genocluster, any candidate vaccine would need 197 
to elicit immunity to GII.4 norovirus strains, and cross-react to antigenically distinct GII.4 variants. A 198 
chimeric VLP was developed incorporating epitopes from antigenically distinct GII.4 viruses82, and 199 
induced broadly-reactive antibody responses83. 200 
A subsequent trial incorporated the chimeric VLP into a GI.1/GII.4 bivalent vaccine formulation and 201 
demonstrated vaccine induced seroconversion in 90% of vaccine recipients, and reduced 202 
gastroenteritis following challenge5. However, the predefined primary endpoints were not achieved in 203 
this study, and further studies are necessary to assess how effective this candidate vaccine would be 204 
in the general population, and specifically in paediatric and elderly populations. Furthermore, studies 205 
must address both the duration of and the inter-/intra-genotype breadth of protection. 206 
 207 
Perspectives 208 
Clearly, significant progress has been made in understanding the virology and epidemiology of 209 
norovirus in humans: but there remain significant gaps in our knowledge, important for development of 210 
therapeutic and preventative interventions, and ascertaining norovirus disease burden to understand 211 
how these should be utilised, and to measure their effectiveness. This is true in all economic settings, 212 
but especially in low economic settings. 213 
One key question is to understand the emergence of norovirus strains. With no animal reservoir17, the 214 
virus must be sustained – and continuously evolve – in the human population. Using genomics 215 
approaches to measure and monitor virus diversity among circulating strains, and to characterise and 216 
measure whether observed genetic changes induce phenotypic changes will be crucial in developing 217 
the systems needed to understand and monitor emergence events, particularly those that lead to rapid 218 
pandemic spread of norovirus strains. There is increasing evidence that children may act as important 219 
reservoirs of norovirus, and the virus may exploit the more naïve immunological background in children 220 
to explore antigenic diversity, ultimately leading to virus diversification and subsequent emergence of 221 
novel strains84. 222 
Second, more detailed understanding of the burden of the disease, transmission dynamics and 223 
pathogenesis in risk groups, both those at risk of more severe disease (immunocompromised85, 224 
elderly61), and those more likely to come into contact with or are at higher risk of transmitting the virus 225 
(food-handlers86, healthcare workers87, military personnel76) is needed. There are complex 226 
epidemiological and virological questions relating to the distribution of norovirus-associated disease in 227 
the population, for whom the disease burden is greatest, as well as understanding host susceptibility 228 
factors. Integrated laboratory and epidemiological studies are crucial to investigate how norovirus is 229 
transmitted, disease attribution via different transmission pathways, how infections can be tracked in 230 
the population and during outbreaks, and what role susceptibility factors such as HBGA phenotype or 231 
the individual microbiome composition may play in norovirus infection, development of disease and 232 
outcomes. 233 
Third, alongside data on the direct burden of disease, enhanced data are needed to understand where 234 
interventions may alleviate transmission and disease overall, as many settings are interlinked. For 235 
example, administering a norovirus vaccine to patients in long term care homes might help prevent 236 
outbreaks in this environment, but might have limited effects on the population as a whole. However, it 237 
may be a worthwhile strategy if vaccination in care homes subsequently prevents outbreaks in hospitals 238 
and reduces bed blocking. 239 
With the recent advances in laboratory culture systems for norovirus7, 88, next generation sequencing 240 
technologies89, improved diagnostics4 and measuring phenotypic characteristics of noroviruses90, there 241 
are new opportunities to advance understanding of this common and important human pathogen. 242 
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